#TEK Tek Capital PLC – US Salt forms Strategic Partnership with MicroSalt

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that MicroSalt has entered into an agreement with US Salt LLC (“US Salt”) for the distribution and delivery of MicroSalt’s low-sodium solutions. “We are proud to work with US […]

#TEK Tekcapital Plc – Appointment to the Board of MicroSalt

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Judith Batchelar OBE has joined the board of MicroSalt.     Judith currently serves as Deputy Chair of the U.K. Environment Agency, sits on UK Research and Innovation’s […]

#ORPH Open Orphan PLC – Director dealings

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has received notification that on 29 September 2022, Yamin ‘Mo’ Khan, Chief Executive Officer of the […]

#POLB Poolbeg Pharma PLC – HC Wainwright Global Investment Conference

12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in […]

#BRES Blencowe Resources – Research Note

Blencowe Resources (“Blencowe” or the “Company”) (BRES:LON), is pleased to note the publication of a new research note by First Equity Limited on the Company’s Orom-Cross graphite project, located in Uganda. In the note, First Equity Limited, using the new PFS numbers, have updated their risked valuation model, based upon a revised NPV8 of $482m […]

#ANA Ananda Developments – Shareholder Update

Ananda’s ambition is to be a leading UK grower and provider of high quality, consistent, carbon zero medical cannabis for the UK and international markets. The Directors of Ananda provide the following update to shareholders.   Research programme In early February 2022, 5 seeds of each of 13 strains of cannabis were planted at the […]

#ORPH Open Orphan Plc – $13.4m Influenza HCS contract win

(AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan plc, has signed a $13.4m contract with a US-based biotechnology company to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model. […]

#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate

6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office.   The Company […]